Emgality

Chemical Namegalcanezumab-gnlm
Dosage FormInjection (subcutaneous; 100 mg/mL, 120 mg/mL)
Drug ClassMonoclonal antibodies
SystemNervous
CompanyEli Lilly and Company
Approval Year2018

Indication

  • Indicated in adults for the preventive treatment of migraine
  • Indicated in adults for the treatment of episodic cluster headache
Last updated on 4/20/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Emgality (Galcanezumab-gnlm) Prescribing Information 2018Eli Lilly and Company, Indianapolis, IN
Document TitleYearSource
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta‑analysis. 2021Journal of Neurology
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. 2021Frontiers in Pharmacology
Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. 2021Cephalalgia
Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): a network meta-analysis of randomized controlled trials. 2021Journal of Neurology
Systematic literature review and Bayesian network meta-analysis of episodic cluster headache drugs. 2021European Review for Medical and Pharmacological Science
Calcitonin gene-related peptide monoclonal antibodies versus botulinum neurotoxin A in the preventive treatment of chronic migraine: an adjusted indirect treatment comparison meta-analysis. 2021Frontiers in Pharmacology
Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials. 2020Therapeutic Advances in Neurological Disorders
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. 2020BMC Neurology
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta‑analysis. 2020Journal of Neurology
Galcanezumab for the management of migraine: a systematic review and meta-analysis of randomized placebo-controlled trials.2020Cureus
CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data. 2019Cephalalgia